Table 2 Baseline characteristics (safety population)a
From: Psychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm
Characteristic | Placebo (N = 97) | Bremelanotide | All pooled (N = 394) | ||
|---|---|---|---|---|---|
0.75 mg (N = 100) | 1.25 mg (N = 99) | 1.75 mg (N = 98) | |||
Age (years), mean (SD) | 37.0 (7.7) | 37.6 (7.8) | 35.7 (7.2) | 37.0 (7.6) | 36.9 (7.6) |
Race, n (%) | |||||
White | 75 (77) | 71 (71) | 65 (66) | 70 (71) | 281 (71) |
Black | 19 (20) | 25 (25) | 32 (32) | 23 (23) | 99 (25) |
Other | 3 (3) | 4 (4) | 2 (2) | 5 (5) | 14 (3) |
Diagnosis, n (%) | |||||
FSAD | 4 (4) | 3 (3) | 3 (3) | 2 (2) | 12 (3) |
HSDD | 24 (25) | 20 (20) | 24 (24) | 24 (24) | 92 (23) |
Mixed | 69 (71) | 77 (77) | 72 (73) | 72 (73) | 290 (74) |
Menses frequency regular, n (%) | 72 (74) | 75 (75) | 86 (87) | 79 (81) | 312 (79) |
Used oral contraception ≤ 30 days before screening, n (%) | 12 (12) | 15 (15) | 11 (11) | 15 (15) | 53 (13) |